INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$1.44
0.11 (8.27%)
▲
5d:
+9.09%
30d:
+2.86%
90d:
-12.2%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
9d
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INM shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $1.44, which is considered extended relative to its 30-day fair value range of $1.33 to $1.39.
Technical Outlook: Technically, INM is in a downtrend. Immediate support is located at $1.31, while resistance sits at $1.54. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: INM scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1288.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INM is in a downtrend. Immediate support is located at $1.31, while resistance sits at $1.54. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: INM scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1288.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.33 -
$1.39
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.3%)
- BULLISH: Trading 1288.9% below Wall St target ($20.00)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.33 -
$1.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.54
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Wall Street Target
$20.00
(+1288.9%)
Revenue Growth (YoY)
-26.2%
Share & Embed Analysis
Last updated: October 26, 2026 12:23 AM ET
Data refreshes hourly during market hours. Next update: 1:23 AM
Data refreshes hourly during market hours. Next update: 1:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$206 | 56 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$56 | 38 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$30 | 47 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
